FNY Investment Advisers’s Recursion Pharmaceuticals RXRX Stock Holding History

FNY Investment Advisers’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,444	Closed	-$14K	–	1049
2025 Q4	$14K	Sell	3,444 -673	-16%	-$3.33K	﹤0.01%	613
2025 Q3	$20K	Buy	4,117 +440	+12%	+$2.31K	0.01%	685
2025 Q2	$18K	Buy	+3,677	New	+$18.1K	0.01%	571
2024 Q3	–	Sell	-1,511	Closed	-$11K	–	801
2024 Q2	$11K	Sell	1,511 -555	-27%	-$4.84K	0.01%	344
2024 Q1	$20	Buy	+2,066	New	+$23K	0.01%	371

Other funds holding RXRX

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

BEI

Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return

PFSRSONJ

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

SFS

Sowell Financial Services North Little Rock, Arkansas $3.06B AUM 30.02% 1-Year Est. Return

CUAMC

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Kieckhefer Group Mequon, Wisconsin $246M AUM 51.29% 1-Year Est. Return

TMC

Themes Management Co Greenwich, Connecticut $151M AUM

Plancorp LLC Saint Louis, Missouri $4.1B AUM 25.19% 1-Year Est. Return

FNY Investment Advisers's RXRX Position: Q1 2026 in Review

FNY Investment Advisers sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 3,444 shares — an estimated $14K sold.

FNY Investment Advisers first reported a position in RXRX in Q1 2024 and held it in 5 quarters. The position peaked at $20K in Q3 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

FNY Investment Advisers reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
FNY Investment Advisers sold 3,444 Recursion Pharmaceuticals shares in Q1 2026, an estimated $14K.
FNY Investment Advisers first reported a position in Recursion Pharmaceuticals in Q1 2024 and held it in 5 quarters.
FNY Investment Advisers's Recursion Pharmaceuticals position peaked at $20K in Q3 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.